ArticleBlood advances2022
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP.
Open access · goldAbstract read
In one paragraph
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Meta-analysis of mortality factors after COVID-19 infection in pediatric oncology patients.Frontiers in oncology · 2025Pooled it
- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.Nature medicine · 2024Pooled it
- 30 years in service, 1996-2026: Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Annals of hematology · 2026Review
- Role of remdesivir for the treatment of COVID-19 in patients with hematologic malignancy-A narrative review and expert opinion.European journal of clinical investigation · 2025Review
- CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.Research square · 2025Article
- Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies.Antibodies (Basel, Switzerland) · 2025Review
- SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy.Annals of hematology · 2025Article
- Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study.JMIR research protocols · 2025Article
- Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective.Infectious diseases and therapy · 2025Review
- Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma.JAMA network open · 2025Observational
- Chimeric antigen receptor T cell therapy for autoimmune disease.Nature reviews. Immunology · 2024Review
- The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19.Seminars in hematology · 2024Review
- Article
- Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey.Infection · 2024Article
- Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.EClinicalMedicine · 2024Article
- Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight.Leukemia research reports · 2024Article
- Chimeric antigen receptor T-cell therapy in autoimmune diseases.Frontiers in immunology · 2024Review
- Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.Frontiers in oncology · 2024Review
- Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy.Clinical hematology international · 2024Review
- Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.Influenza and other respiratory viruses · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 20 institutions in 14 countries.
Alessandro BuscaStem Cell Transplant Center, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin, Italy.ORCID 0000-0001-5361-5613
Jon Salmanton-GarcíaDepartment I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, Cologne, Germany.ORCID 0000-0002-6766-8297
Paolo CorradiniUniversity of Milan and Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0002-9186-1353
Francesco MarchesiHematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.ORCID 0000-0001-6353-2272
Alba CabirtaDepartment of Hematology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Istitute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0001-7198-8894
Roberta Di BlasiHôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.ORCID 0000-0001-9001-573X
Remy DuleryService d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Unité Mixte de Recherche (UMR) 938, Sorbonne Universitè, Paris, France.ORCID 0000-0002-5024-1713
Sylvain LamureDepartment of Clinical Hematology, Montpellier University Hospital, IGMM UMR1535 CNRS, University of Montpellier, Montpellier, France.ORCID 0000-0001-5980-305X
Francesca FarinaIRCCS Ospedale San Raffaele, Milan, Italy.ORCID 0000-0002-4350-3105
Barbora WeinbergerováDepartment of Internal Medicine-Hematology and Oncology, Masaryk University Hospital Brno, Brno, Czech Republic.ORCID 0000-0001-6460-2471
Josip BatinićUniversity Hospital Centre Zagreb, Zagreb, Croatia.ORCID 0000-0001-5595-9911
Anna NordlanderDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Alberto López-GarcíaFundacion Jimenez-Díaz, Madrid, Spain.ORCID 0000-0002-5354-5261
Ľuboš DrgoňaComenius University and National Cancer Institute, Bratislava, Slovakia.ORCID 0000-0002-5089-3201
Ildefonso Espigado-TocinoHospital Univesitario Virgen del Rocío, Seville, Spain.ORCID 0000-0002-4043-6613
Iker Falces-RomeroLa Paz University Hospital, Madrid, Spain.
Ramón García-SanzHospital Universitario de Salamanca, Salamanca, Spain.ORCID 0000-0003-4120-2787
Carolina García-VidalHospital Clinic, Barcelona, Spain.ORCID 0000-0002-8915-0683
Anna GuidettiDivision of Hematology and Bone Marrow Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milan, Italy.ORCID 0000-0002-4195-6397
Nina KhannaDivision of Infectious Diseases and Hospital Epidemiology, Department of Clinical Research, University and University Hospital of Basel, Basel, Switzerland.ORCID 0000-0002-2642-419X
Austin KulasekararajKing's College Hospital, London, United Kingdom.ORCID 0000-0003-3180-3570
Johan MaertensKatholieke Universiteit Leuven, Leuven, Belgium.ORCID 0000-0003-4257-5980
Martin HoeniglDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA.ORCID 0000-0002-1653-2824
Nikolai KlimkoDepartment of Clinical Mycology, Allergy and Immunology, North Western State Medical University, St Petersburg, Russia.ORCID 0000-0001-6095-7531
Philipp KoehlerDepartment I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, Cologne, Germany.ORCID 0000-0002-7386-7495
Antonio PagliucaDepartment of Hematological Medicine, Kings College Hospital, National Health Service Foundation Trust, London, United Kingdom.ORCID 0000-0003-2519-0333
Francesco PassamontiDepartment of Medicine and Surgery, University of Insubria and Azienda Socio Sanitaria Territoriale Sette Laghi, Ospedale di Circolo of Varese, Varese, Italy.ORCID 0000-0001-8068-5289
Oliver A CornelyDepartment I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, Cologne, Germany.ORCID 0000-0001-9599-3137
Livio PaganoHematology, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy; and.ORCID 0000-0001-8287-928X
Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases · DEUniversity of Milan · ITAssistance Publique – Hôpitaux de Paris · FRAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITCentre National de la Recherche Scientifique · FRComenius University Bratislava · SKComplejo Hospitalario de Salamanca · ESCroatian Chamber of Economy · HRHospital Clínic de Barcelona · ESHospital Universitario Fundación Jiménez Díaz · ESHospital Universitario La Paz · ESHospital Universitario Virgen del Rocío · ESIRCCS Ospedale San Raffaele · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITKarolinska University Hospital · SEKing's College Hospital · GBKU Leuven · BEMasaryk University · CZMedical University of Graz · ATNational Health Service · GB
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19Receptors, Chimeric AntigenHumansImmunotherapy, AdoptiveT-LymphocytesReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.